Aesculap receives FDA Approval for the activL® Artificial Disc for One-Level Lumbar Use
Intelligent Motion Technology for total disc replacement; activL is designed as an alternative to spinal fusion surgery to allow motion at the treated level of the lower back.Aesculap Implant Systems, LLC (Aesculap) a privately held medical device company, announced today that it has received a letter of approval from the U.S. Food and Drug Administration (FDA) allowing the commercial sale of the activL® Artificial Disc, for the treatment of one-level lumbar degenerative disc disease.
Chuck DiNardo, Aesculap President commented, "We are very pleased that the FDA has determined activL to